The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2019

Filed:

Apr. 07, 2015
Applicants:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Novartis Ag, Basel, CH;

Inventors:

Carl H. June, Merion Station, PA (US);

David L. Porter, Springfield, PA (US);

Marcela Maus, Bryn Mawr, PA (US);

Mariusz Wasik, Ardmore, PA (US);

Saar Gill, Philadelphia, PA (US);

Joseph Fraietta, Cherry Hill, NJ (US);

Marco Ruella, Philadelphia, PA (US);

John Byrd, Columbus, OH (US);

Jason Dubovsky, Columbus, OH (US);

Amy Johnson, Dublin, OH (US);

Natarajan Muthusamy, Galloway, OH (US);

Saad Kenderian, Philadelphia, PA (US);

Joan Mannick, Cambridge, MA (US);

David Glass, Cambridge, MA (US);

Leon Murphy, Cambridge, MA (US);

Jennifer Brogdon, Cambridge, MA (US);

William Raj Sellers, Cambridge, MA (US);

Assignees:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); A61K 31/436 (2006.01); A61K 31/53 (2006.01); C12N 5/0783 (2010.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C12N 2501/599 (2013.01); C12N 2501/727 (2013.01); C12N 2510/00 (2013.01);
Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.


Find Patent Forward Citations

Loading…